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Different from canonical ubiquitin-like proteins, Hub1 does not form covalent conjugates with substrates but binds proteins non-
covalently. In Saccharomyces cerevisiae, Hub1 associates with spliceosomes and mediates alternative splicing of SRC1, without
affecting pre-mRNA splicing generally. Human Hub1 is highly similar to its yeast homolog, but its cellular function remains largely
unexplored. Here, we show that human Hub1 binds to the spliceosomal protein Snu66 as in yeast; however, unlike its S. cerevisiae
homolog, humanHub1 is essential for viability. Prolonged in vivodepletion of human Hub1 leads to various cellular defects, including
splicing speckle abnormalities, partial nuclear retention of mRNAs, mitotic catastrophe, and consequently cell death by apoptosis.
Early consequences of Hub1 depletion are severe splicing defects, however, only for specific splice sites leading to exon skipping
and intron retention. Thus, the ubiquitin-like protein Hub1 is not a canonical spliceosomal factor needed generally for splicing, but
rather a modulator of spliceosome performance and facilitator of alternative splicing.
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Introduction
Ubiquitin family proteins (ubiquitin, SUMO, Rub1/Nedd8, etc.)
are central regulators of cellular functions (Hochstrasser, 2000).
Canonical members of this protein family are enzymatically and
reversibly conjugated to other proteins, thereby functioning as
covalent protein ‘modifiers’. Although structurally very similar to
ubiquitin (McNally et al., 2003; Ramelot et al., 2003), the highly
conserved protein Hub1 does not function as a covalent modifier
but binds proteins only non-covalently (Luders et al., 2003;
Yashiroda and Tanaka, 2004; Mishra et al., 2011). In
Saccharomyces cerevisiae, Hub1 binds tightly to the spliceosomal
protein Snu66, a protein of the U4/U6.U5 small nuclear ribonucleic
particle (tri-snRNP) (Wilkinson et al., 2004; Mishra et al., 2011).
However, contesting earlier reports (Dittmar et al., 2002;
Wilkinson et al., 2004), we have shown previously that yeast
Hub1 is not required to localize Snu66 to the nucleus, but that
Hub1 affects splicing directly through non-covalent interactions
(Mishra et al., 2011). Snu66 of S. cerevisiae possesses near its
amino (N)-terminus two tandem-arranged Hub1 interaction
domains, termed HIND, enabling the splicing factor to bind up to
two Hub1 molecules (Mishra et al., 2011). In S. cerevisiae, Hub1
is not essential for viability and is apparently also not generally
required for splicing as judged by splicing-sensitive microarray
assays (Mishra et al., 2011). Intriguingly, hub1D cells fail to
promote alternative splicing of SRC1, which is one of the rare
cases of S. cerevisiae genes for which alternative splicing has
been reported. Abolishing Hub1–Snu66 interaction by mutation
affects SRC1 alternative splicing as well (Mishra et al., 2011), sug-
gesting that binding of Hub1 to Snu66 is critical for Hub1’s function
in S. cerevisiae. Since also SRC1 is not essential for viability, it
seems possible that the function of Hub1 of S. cerevisiae is
restricted to SRC1. In contrast, in Schizosaccharomyces pombe,
in which splicing is much more prevalent than in S. cerevisiae,
Hub1 affects splicing of several pre-mRNAs and is essential for via-
bility (Yashiroda and Tanaka, 2004; Mishra et al., 2011).Received February 28, 2014. Revised April 11, 2014. Accepted April 23, 2014.
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Contrasting these detailed findings, much less is known about
Hub1 from higher eukaryotes. Human Hub1 (also known as UBL5
or beacon) appears to be exported from the nucleus upon
hypo-osmic shock (Hatanaka et al., 2006), and known to bind
certain protein kinases (Kantham et al., 2003). Hub1 has been
detected in human spliceosomes by mass spectrometry (Deckert
et al., 2006) and reported to be implicated in pre-mRNA splicing
(Sˇve´da et al., 2013; Laetsch et al., 2014), but a detailed character-
ization of the cellular function of mammalian Hub1 was lacking.
In the nematode Caenorhabditis elegans, Hub1 was identified
in a genetic screen for genes implicated in the unfolded protein re-
sponse in mitochondria (UPRmt) (Benedetti et al., 2006). Moreover,
co-immunoprecipitation experiments from cell extracts suggested
that C. elegans and mammalian Hub1 associates with the DVE-1
transcription factor responsible for the UPRmt pathway (Haynes
et al., 2007). However, whether Hub1 binds the transcription
factor directly and controls transcription has not been tested.
Similarly, the mammalian homolog of Snu66, termed hSnu66 or
SART1, has been suggested to modulate transcription as well
(Gupta et al., 2000), but in vitro splicing assays with human
nuclear extracts have shown that hSnu66 is crucial for splicing
and present in spliceosomes as in yeast (Makarova et al., 2001;
Liu et al., 2006; Bessonov et al., 2008).
Here we address the cellular role of human Hub1 biochemically
as well as functionally by siRNA-mediated depletion. Our study
revealed a strong conservation of Hub1 and its binding to Snu66
at the molecular level. However, we found that Hub1 is much more
important for human cells than for S. cerevisiae, and also describe
that Hub1 depletion causes splicing speckle abnormalities and
mitotic defects culminating in caspase-mediated apoptosis.
Importantly, Hub1 does not seem to influence splicing of all splice
substrates equally, but to facilitate only certain splicing events of
particular introns/exons of pre-mRNAs. These findings thus lead
to the model that the ubiquitin-like protein Hub1 plays a conserved
role in the spliceosome as modulator of splicing activity.
Results
Human Hub12Snu66 complex
To address whether human Hub1 is involved in splicing, we first
asked whether expression of human Hub1 could complement the
phenotypes of the Hub1 deletion mutants of S. cerevisiae and
S. pombe. Since S. cerevisiae strains with a deletion of the
Hub1-encoding gene (hub1D) are viable and cells exhibit no dis-
cernable growth defects, we rather assayed in a genetic background
(prp8*, partially defective in the spliceosomal protein Prp8) in
which Hub1 becomes essential for viability (Mishra et al., 2011).
Notably, although both S. pombe and human Hub1-encoding
genes could rescue the synthetic lethality of the hub1D prp8*
double mutant, human Hub1was unable to do so at higher tempera-
tures (Figure 1A; top panel; for protein levels see Supplementary
Figure S1A). Moreover, the defect in alternative SRC1 splicing of
the S. cerevisiae hub1D mutant (Mishra et al., 2011) was consider-
ably rescued by S. pombe Hub1 but only weakly by human Hub1
(Figure 1B). Conversely, when we assayed for complementation of
the S. pombe hub1D mutant, we found that expression of human
Hub1 rescued the lethality of this mutant like S. pombe Hub1,
whereas expression of the S. cerevisiae gene provided viability,
yet the strain exhibited a mild growth phenotype (Figure 1A;
bottom panel; for protein levels see Supplementary Figure S1B).
Thus, echoing the sequence divergence of the various Hub1
proteins, human and S. pombe Hub1 are functionally similar,
whereas S. cerevisiae Hub1 is divergent to some degree.
Hub1 of yeast and mammalian cells associates with the spliceo-
some through interaction with the tri-snRNP protein Snu66 (Mishra
et al., 2011). Unlike S. cerevisiae Snu66, which possesses
two tandem-arranged HIND elements in its N-terminal domain,
S. pombe and human Snu66 proteins harbor only one element
(Mishra et al., 2011). In contrast to its S. cerevisiae counterpart,
human Snu66 (referred to hSnu66 in the following) harbors an ar-
ginine/serine rich (RS) domain (aa41–108) directly N-terminally of
its HIND motif (Makarova et al., 2001). Because RS domains can
mediate protein–protein interactions as well (Wu and Maniatis,
1993; Wang et al., 1995), we mapped the Hub1-binding site
using hSnu66 truncations and found that the single HIND motif
of hSnu66 is sufficient and necessary for Hub1 binding (Figure 2A
and Supplementary Figure S2A).
To characterize the Hub1–HIND interaction further, we obtained
structural information of human Hub1 in complex with a peptide
corresponding to the single human HIND sequence (Figure 2B and
Supplementary Figure S2B). The solved crystal structure (PDB
code4PYU) with a resolution of2.0 A˚ highlights the typical ubiquitin
b-grasp fold of human Hub1, with the typical bbabab secondary
structure pattern, as described previously (McNally et al., 2003;
Ramelot et al., 2003). The interaction between Hub1 and the
a-helical HIND peptide is mediated through a salt bridge formed
byD22ofHub1andR127ofHIND, strengthened byhydrophobic con-
tacts involving aliphatic fragments of residues of hSnu66’s HIND and
the Hub1 interface (Figure 2B). Although Hub1possesses an ubiqui-
tin fold, it uses the opposite protein surface for Snu66 binding com-
pared to ubiquitin for binding to ubiquitin receptors like Rad23
(Mishra et al., 2011). The X-ray analysis revealed that human and
S. cerevisiaeHub1-HIND complexes have overall very similar, super-
imposable structures with a root mean squared deviation (RMSD) of
0.716 A˚. The two structures only show small differences, particularly
in protein loops extending opposite of the Hub1–HIND interaction
surface (Supplementary Figure S2C).
Testing the relevance of the salt bridge between D22of Hub1and
R127 of the HIND element for this interaction, we found that a
recombinant fusion protein of GFP with the N-terminal domain of
hSnu66 (aa 1–139), but not a similar fragment bearing an
alanine replacement of a the R127 residue (R127A) in its HIND
domain, bound endogenous Hub1 of human cell extracts in
GFP-immunoprecipitation assays (Figure 2C). Conversely, only
immunoprecipitation of stably expressed GFP-fusions of wild-type
(WT) Hub1 but not of a Hub1 variant harboring an alanine replace-
ment of the D22 residue (D22A) co-isolated endogenous hSnu66
from human cell lysates (Figure 2D). From these findings we infer
that binding of human Hub1 to Snu66 does indeed depended on
the integrity of this salt bridge, showing that physical properties
of Hub1 are highly conserved at the molecular level.










Hub1 is essential for viability of human cell lines
We next addressed the cellular importance of human Hub1 by in
vivo depletion of Hub1 from human cells using RNAi. Transfection
of Hub1 siRNA led to an efficient depletion of the Hub1 protein in
cell cultures (Supplementary Figure S3A). Live cell imaging
revealed that 48 h after siRNA treatment, cells start to exhibit
strong cell cycle progression delays, accompanied by defects in
mitotic cell division, for instance in metaphase plate formation
and chromosome segregation (Figure 3A and B). Flow cytometry
analysis showed that Hub1 siRNA treatment initially (after 48 h)
caused defects in G2/M cell cycle progression, and culminated
later (72 h) in a rise of sub-G1 fractions, indicative of cells undergo-
ing apoptosis (Figure 3C). We also induced cell cycle arrest in
S-phase in Hub1 siRNA-treated cells using a double thymidine
block, and monitored synchronous cell cycle progression after
release from the block by a washing step. Again we found that
Hub1 siRNA-treated cells, but not cells treated with a control
siRNA, exhibited G2/M cell cycle progression defects 9 h after
S-phase release (Supplementary Figure S3B). Prolonged Hub1
siRNA treatment led to aberrant mitosis with characteristics of
mitotic catastrophe (mitosis-linked cell death) as indicated by
live cell imaging as well as a-tubulin staining (Figure 3A and D).
The observed defects included chromosome mis-segregation and
loss of nuclear integrity, which gave rise to segmented nuclei and
later apoptosis.
Indeed, apoptosis was caspase-dependent and affected the ma-
jority of Hub1 siRNA-treated cells as indicated by the efficiency of
caspase-7 cleavage and annexin V/PI stainings (Supplementary
Figure S3C and D). Transfection of an siRNA-resistant Hub1 cDNA
restored WT phenotypes to Hub1 siRNA-treated cells (Figure 3E
and Supplementary Figure S3E), verifying that the observed pheno-
types were caused by Hub1 depletion. Notably, a siRNA-resistant
cDNA expressing a Hub1 variant deficient in Snu66 interaction
(D22A) rescued viability only partially, indicating that binding of
Hub1 specifically to the spliceosomal protein hSnu66 might con-
tribute, but may not be as critical in humans as in S. cerevisiae.
Depletion of human Hub1 causes splicing speckle abnormalities
The physical interaction of Hub1with spliceosomal components
like hSnu66 and SR-protein Cdc2/cdc28-like kinases (Clk)
(Kantham et al., 2003) emphasizes the link between Hub1 and
the pre-mRNA splicing machinery. Localization studies using im-
munofluorescence microscopy showed that Hub1 resides in
so-called splicing speckles, i.e. splicing factor-associated nuclear
assemblies that appear microscopically as irregular punctate
nuclear structures (Lamond and Spector, 2003). In these splicing
speckles, human Hub1 co-localizes with characteristic nuclear
speckle markers, like the serine/arginine-rich (SR) protein SC35
(alias SRSF2; Huang and Spector, 1992), the U1 snRNP (identified
with anti-U1A antibody; Sleeman et al., 1998), and snRNP-specific
Sm proteins (identified with Y12 antibody; Lerner et al., 1981)
(Figure 4A). Our previous work showed that hSnu66 is able to
recruit Hub1 to nuclear speckles via its HIND element upon transi-
ent Hub1 and hSnu66 co-overexpression (Mishra et al., 2011). Yet,
when Hub1 was stably expressed, nuclear speckle localization of
Hub1 (GFP-Hub1) was largely normal even when Hub1 was defi-
cient in HIND interaction (D22A mutant variant; Supplementary
Figure S4A). Thus, human Hub1 is able to associate with splicing
speckles also independently of Snu66. This finding supports the
above observation (Figure 3E) that binding of Hub1 to Snu66 is
not essential for Hub1 function, and suggests that other surfaces
of Hub1 may contribute to splicing factor association.
Splicing speckles are typically highly dynamic as some of their
protein and RNA content cycle continuously between speckles,
sites of transcription and other nuclear locations (Misteli et al.,
1997; Politz et al., 2006; Spector and Lamond, 2011). The splicing
Figure 1 Conserved and divergent properties of Hub1. (A) Genetic complementation assays. Rescue of synthetic sickness of hub1Dprp8* in
S. cerevisiae (top panel) and lethality of hub1D in S. pombe (bottom panel), by expression of Hub1-encoding genes (or cDNAs) from S. cerevisiae
(Sc),S. pombe (Sp), andH. sapiens (Hs). For complementation inS. pombe, aURA4-bearing plasmid expressing WT SpHUB1was shuffled-out from
the hub1D strain by counter-selection with FOA. Growth assays with 5-fold serial dilutions on control or FOA-containing plates at indicated tem-
perature are shown. (B) Complementation of altered alternative splicing ofS. cerevisiae SRC1 in hub1Dprp8* cells by HUB1 orthologs at308C (like
in A). Protein expression levels of TAP-tagged Src1-L and Src1-S isoforms as well as Hub1 were monitored by immunoblotting using anti-TAP and
anti-Hub1 antibodies, as described previously (Mishra et al., 2011). The quantification of the relative ratio between Src1-L and Src1-S isoforms is
given below.










protein SC35, for example, also associates with sites of active tran-
scription where it promotes transcriptional elongation via binding
to the C-terminal domain of RNA polymerase II (Lin et al., 2008).
Moreover, splicing and mRNA export are often coupled (Jime´nez-
Garcı´a and Spector, 1993) and hence partly spliced mRNAs accu-
mulate in the nucleus upon splicing inhibition (Kaida et al.,
2007). Because of Hub1’s association with components of the
splicing machinery in nuclear speckles and the observed strong
phenotypes associated with Hub1 depletion in human cells at
later stages of knockdown, we asked whether Hub1 influences
the structure of splicing speckles and the nuclear shuttling of
mRNA. Indeed, when we transfected Hub1 siRNA into cells, the
SC35, 3mG cap (2,2,7-trimethylguanosine cap of non-U6 snRNPs)
and U1A-positive speckles become larger but less abundant
already at time points at which cells exhibited no signs of degener-
ation (Figure 4B and Supplementary Figure S4B–D). We next
addressed whether the Hub1 RNAi-dependent changes in nuclear
speckle distribution are linked to defects in nuclear mRNA distribu-
tion. Indeed, fluorescence in situ hybridization (FISH) using poly
(dT) probes revealed an moderate nuclear accumulation and
enrichment of poly-adenylated RNA in nuclear speckles in Hub1
siRNA-treated cells compared with control cells (Figure 4B and
Supplementary Figure S4B and D). The observed RNA accumulation
was similar to cells in which splicing was repressed by the splicing
inhibitor spliceostatin A (Kaida et al., 2007), repressing oligonucleo-
tides that target U1 or U6 snRNAs (O’Keefe et al., 1994) or RNAi
(Tanackovic and Kra¨mer, 2005), further indicating that human cells
lacking Hub1 suffer from defective pre-mRNA processing.
Hub1 is crucial for splicing of certain introns
The strong phenotype associated with Hub1 depletion in human
cells suggests that human Hub1 plays a much more fundamental
cellular role than its S. cerevisiae counterpart. Reasonable
models are that Hub1 is crucial in human cells either for general
splicing, for splicing of certain pre-mRNAs or of particularly sensi-
tive splicing reactions at suboptimal splice sites. To address spli-
cing competence of Hub1-depleted tissue culture cells, we first
analyzed splicing of model transcripts that are known to undergo
alternative splicing in humans. To this end, we used a minigene ap-
proach (Stoss et al., 1999) by expressing genomic fragments of
Figure 2 Molecular mode of interaction between human Hub1 and HIND. (A) Mapping of the Hub1 interaction domain in hSnu66 using
FLAG-immunoprecipitation of 3xFLAG-Hub1 after co-expression of GFP-tagged hSnu66 truncations or free GFP in human cells.
Immunoprecipitates were immunoblotted with anti-FLAG and anti-GFP antibodies (Asterisks indicate light and heavy chains). (B) Crystal structure
of human Hub1 (blue) in complex with HIND peptide (pink) of hSnu66 shown as a ribbon plot with a resolution of 2.0 A˚. The interaction between
Hub1 and the a-helical HIND peptide is mediated through a salt bridge formed by D22 of Hub1 and R127 of HIND, strengthened by hydrophobic
contacts involving aliphatic fragments of residues of hSnu66’s HIND (L118, I120, T123, L126, R127 (Cb and Cg), L130, L132, L135) and the Hub1
interface (M1, V16, L17 (Cb, Cg, Cd), C18, N19 (Cb, Cg), L29 (Cb, Cg, Cd), L30, A33). (C) GFP-directed immunoprecipitation of GFP fused to the HIND
containing N-terminal domain (aa1–139) of wild-type hSnu66 (WT) or Hub1-binding-deficient HIND mutant (R127A). Immunoblot detection using
antibodies directed against GFP, human Hub1, ora-tubulin (control). (D) Co-immunoprecipitation of Hub1with hSnu66depends on the HIND inter-
action interface. GFP immunoprecipitation from U2OS cells stably expressing GFP-tagged Hub1 WT or hSnu66 binding mutant Hub1 D22A.
Immunoblots were probed with anti-GFP and anti-hSnu66 antibodies with anti-U2AF65 serving as a loading control.










Figure 3 Human Hub1 is essential for viability. (A) Live cell microscopy of H2B-GFP HeLa cells treated with RNAi against Hub1 or non-targeting
control. The images represent stills of time-lapse video microscopy at representative time points 60 h post transfection. Scale bar, 10 mm. (B)
Quantification of cell cycle delay after Hub1 knockdown by measuring time in mitosis from nuclear envelope breakdown until completion of
mitosis by live cell microscopy of H2B-GFP HeLa cells. Data represent mean and standard deviation (SD) for control RNAi (n ¼ 30) and Hub1
RNAi (n ¼ 56). (C) Flow cytometry analysis of cell cycle distribution and induction of apoptosis after Hub1 depletion 48 or 72 h post transfection.
Quantifications for the sub-G1 fractions are shown next to the flow cytometry profiles. (D) Representative images of HeLa cells 72 h after RNAi
transfection exhibiting loss of nuclear integrity and structural abnormalities. In contrast to wild type or control RNAi-treated cells where nuclei
were integer and regular in shape with a typical outspread a-tubulin network, Hub1 RNAi-treated cells exhibited deformed and disintegrated
nuclei, segmented into multiple micronuclei that were radially arranged around central dense a-tubulin material. Immunofluorescence staining
with anti-a-tubulin antibodies (green) and DAPI visualizes structural abnormalities and nuclear rearrangements. Scale bar, 10 mm. (E)
Complementation of Hub1 RNAi by expression of siRNA-resistant Hub1 encoding WT or Hub1 D22A mutant. Analysis of cell cycle distribution
and induction of apoptosis by flow cytometry with quantification of apoptotic sub-G1 fraction in Hub1 complementation assays (right panel,
data represent mean and SD of three independent experiments). Due to highest knockdown efficiency Hub1 depletion and complementation
experiments were performed using siRNA oligo iHub1_1.










genes for fibronectin 1 (FN1, exon 31–34 including ED-A exon;
Muro et al., 1999), tropomyosin 1a (TPM, exon 3–6; Graham
et al., 1992) or myeloid cell leukemia sequence 1 (MCL1, exon 1–2;
Bae et al., 2000) in U2OS or HeLa cells after treatment with Hub1
siRNA or control siRNA for 48 h, during which neither aberrant
mitosis nor viability defects were detectable. Using minigene-
specific primers, we measured splicing efficiency by RT–PCR of iso-
lated total RNA. In this setup, Hub1 depletion resulted in different
forms of alternative and constitutive splicing defects. In case of
FN1, Hub1 depletion caused exon (ED-A) skipping, whereas
intron retention coupled to moderately lower steady state mRNA
levels was observed for TPM and MCL1 (Figure 5A).
To determine whether Hub1 depletion also affects endogenous
pre-mRNAs, we tested splicing of transcripts that are known to
harbor weak splice sites by intron-spanning RT–PCR (Ahn et al.,
2011). By these assays we observed different degrees of splicing
defects for introns of the tested genes AKT, RAD23A, and AURKA
(aurora kinase A), whereas tubulin pre-mRNA was spliced normally
(Figure 5B). The observed defects could be directly attributed
to RNAi-mediated Hub1 deficiency as indicated by complementa-
tion experiments using Hub1 siRNA-insensitive GFP-Hub1 cDNAs
(Supplementary Figure S5A and B). Furthermore, since cDNA
encoding a Hub1 variant deficient in hSnu66-binding (Hub1-
D22A) complemented the splicing defects, yet perhaps not as
well (Supplementary Figure S5A and B), direct binding of Hub1 to
hSnu66 via the HIND element is apparently not strictly essential
for Hub1-dependent splicing in humans.
We next compared the splicing defects linked to Hub1 depletion
with splicing defects induced by depletion of the tri-snRNP protein
hSnu66 or the SR protein Son, which supports splicing for a subset
of human pre-mRNAs (Sharma et al.,2011). Whereas Hub1and Son
seemed important for efficientAKT splicing, Hub1 and hSnu66 (but
apparently not Son) facilitated splicing of MCL1 and AURKA
(Figure 5C and Supplementary Figure S5D). Furthermore, detailed
mapping studies of Hub1-sensitive transcripts by analyzing flank-
ing exonic and intronic sequences revealed that Hub1 depletion
caused splicing defects only for some introns, while other introns
of the same pre-mRNAs were processed normally (Figure 5C).
Notably, the observed splicing defects of these pre-mRNAs that
occurred upon Hub1 depletion could also be verified using sub-
cloned fragments in minigene splicing assays (Supplementary
Figure S5C). This suggests that the effect of Hub1 on splicing
does not require the native pre-mRNA or genomic chromatin,
which can influence splice site selection.
Figure 4 Depletion of Hub1 causes nuclear speckle abnormalities. (A) Co-localization studies in U2OS cells stably expressing GFP-Hub1 (green).
Cells were pre-extracted, fixed, and immunostained for splicing proteins (red) using antibodies against nuclear speckle marker phospho-SC35, U1
snRNP (anti-U1A antibody), and snRNP associated Sm proteins (anti-Y12), respectively. Scale bar, 10 mm. (B) Visualization of poly-adenylated
mRNA by FISH with fluorescently labeled poly-(dT)-TRITC probes co-stained for nuclear speckles with anti-SC35 antibodies in U2OS cells
treated with Hub1 or control RNAi. Scale bar, 10 mm. The nuclear accumulation of poly-adenylated mRNA upon Hub1 knockdown is quantified
by measuring the integrated FISH signal as arbitrary intensity units per area in nuclear and cytoplasmic compartments. The box-and-whisker
plots represent the quantification of two independent experiments with significant differences between Hub1 and control RNAi treated cells (P
as the probability of a two-tailed paired t-test, n . 140 for control cells and n . 239 for Hub1 knockdown cells).










To analyze the role of Hub1 for splicing events further we also
undertook a genome-wide approach using a splicing-sensitive
microarray. To this end, we performed exon-level expression profil-
ing using the Affymetrix GeneChip Human Exon 1.0 ST array which
allows the detection of alternative splicing events by multiple
probes per exon along the entire length of a transcript (Clark
et al., 2007). Bioinformatic analysis of the microarray core set iden-
tified .3000 altered splicing events in total (63707 probe sets
tested) for distinct exons after Hub1 RNAi treatment compared
with control RNAi treated U2OS cells (Geo Series Accession
Number: GSE56878; Supplementary Table S3 and Figure S5E),
further corroborating a substantial impact of Hub1 on a number
of splice substrates. Thus, various lines of evidence indicate that
Hub1 is not generally essential for splicing but crucial for only
some particular splicing events leading to alternative splicing in
human cells. Moreover and importantly, only certain splicing
events for a given pre-mRNA are affected by Hub1-depletion, dem-
onstrating that the requirement for Hub1 is not restricted to a
certain class of mRNA species.
Discussion
Posttranslational modification of proteins by members of the
ubiquitin family affects numerous cellular functions. Due to the
presence of modifier-conjugating and de-conjugating enzymes,
Figure 5 Hub1 is crucial for mRNA splicing of certain introns. (A) Alteration in alternative splicing of minigenes upon Hub1-depletion. Genomic frag-
ments of tropomyosin1a (TPM, exon3–6), myeloid cell leukemiasequence1 (BCL2-related) (Mcl-1, exon1–2), or fibronectin1 (FN1, exon31–34 incl.
ED-A) (see schematic exon-intron structure) expressed as minigenes in U2OS cells, and their mRNA products were analyzed by minigene-specific RT–
PCR afterHub1orcontrol RNAi. (B) Detection of aberrant splicing of endogenoustranscripts of v-akt murinethymoma viraloncogenehomolog1 (AKT),
RAD23 homolog A (RAD23A), and Aurora kinase A (AURKA) after Hub1 knockdown by intron-spanning RT–PCR. (C) Detailed characterization of spli-
cing specificities dependent on Hub1 and comparison to splicing factors hSnu66 and Son. Splicing of Hub1-dependent introns and flanking exons in
AKT, AURKA, and MCL1 mRNAs after RNAi against Hub1, hSnu66, and Son in U2OS cells analyzed by gene-specific RT–PCR. Primer sets indicate
Hub1-sensitive introns in the respective transcripts tested in RNAi experiments (red arrow heads), whereas mapping studies with PCR primers
located in flanking sequences (black arrow head) detected no splicing alterations in neighboring exons/introns.










these pathways often function as switches or reversibly control
protein–protein interactions. Even though Hub1 is structurally
very similar to canonical ubiquitin-like proteins (McNally et al.,
2003; Ramelot et al., 2003), the mode of action of Hub1 is very
different. Comprising solely the ubiquitin-fold and lacking N- or
C-terminal extensions, Hub1 is only able to function through non-
covalent interactions with other proteins (Luders et al., 2003;
Yashiroda and Tanaka, 2004; Mishra et al., 2011). So far only
binding of Hub1 to the spliceosome has been functionally con-
firmed and studied at the molecular level in yeast. In the spliceo-
some, a conserved binding partner of Hub1 is the tri-snRNP
protein Snu66. Remarkably, the highly conserved Hub1-binding
HIND element is found in Snu66 of yeast and vertebrates, but on
Prp38, another tri-snRNP protein, in plants (Mishra et al., 2011).
Moreover, in Plasmodium, both Snu66 and Prp38 homologs
contain HIND elements capable in Hub1binding. This phenomenon
suggests that Hub1 binding is not crucial for its respective direct
binding partner, but rather for the functional complex, the spliceo-
some. Since clear HIND elements are apparently not found in other
proteins (Mishra et al., 2011), HIND elements seem to be specific
for spliceosomal Hub1 recruitment and function.
With our new data on human Hub1we are now in the position to
compare the significance of Hub1 for different organisms and to
identify the conserved and general role of Hub1 for pre-mRNA spli-
cing. Based on protein–protein interaction studies and structural
data, here we revealed the mechanism of binding of human Hub1
to Snu66 via the HIND element. Compared with non-covalent
binding interfaces of ubiquitin and ubiquitin-like proteins, the
Hub1–HIND structure highlights a unique mode of interaction
and binding paradigm (Mishra et al., 2011). Several ubiquitin-
binding domains (UBDs) have been identified and crystalized in
complex with the ubiquitin protein. The vast majority of UBDs asso-
ciate with ubiquitin via the hydrophobic area around I44 supported
by L8 and V70 on sheets b3b4 (Dikic et al., 2009). In contrast, the
Hub1–HIND interaction surface is located on the opposite side to
the canonical UBD patch formed by helix a1 and sheets b1b2.
Moreover, the Hub1–HIND complex also clearly differs from the
non-covalent interaction of other ubiquitin-like modifiers like
SUMO with its SIM (SUMO interaction motif; Song et al., 2005)
and the Atg8 homolog LC3 with its interaction region (LIR) (Noda
et al., 2008). We show that the mode of Hub1 binding to Snu66 is
precisely conserved at the molecular level from S. cerevisiae to
humans, while this specific interaction appears to be particularly
relevant for S. cerevisiae. On the other hand, since only a relatively
small portion of the surface of Hub1 is directly involved in Snu66
binding, it is conceivable that different surface areas of Hub1
make additional contacts with Snu66 or other proteins of the
spliceosome.
InS. cerevisiae, for which it is assumed that the majority of origin-
al introns had been eliminated during evolution (Fink, 1987), Hub1
is not essential for viability and apparently functionally restricted to
promote alternative splicing of SRC1 pre-mRNA, which encodes a
non-essential protein (Mishra et al., 2011). This currently only
known Hub1-regulated target is also a yeast rarity since alternative
splicing in S. cerevisiae is extremely rare. Notably, Hub1 becomes
vital for S. cerevisiae if these cells are additionally partially defect-
ive in certain spliceosomal proteins like Prp8 (Mishra et al., 2011).
From these lines of evidence we thus infer that splicing conducted
by spliceosomes containing Hub1 is generally more robust by
tolerating suboptimal splicing conditions.
Hub1 is essential for viability in human cells most likely because
a large number of pre-mRNAs require Hub1 for optimal and correct
splicing of its introns. Judging from our assays, a significant portion
of splicing events in human cells entail Hub1 for normal (WT) spli-
cing, although many other splicing events, even those from the
same pre-mRNAs, were not affected by Hub1 depletion at all.
Since the splice sites of the investigated introns that are sensitive
to Hub1 show no obvious sequence similarity, Hub1 may act as a
splicing qualifying factor for splicing events that are suboptimal
for different reasons, e.g. due to pre-mRNA folding constrains (sec-
ondary structures) or the presence of bound proteins. Moreover, as
indicated by our minigene and microarray data, Hub1-stimulated
RNA processing affects a broad spectrum of splice events in
various transcripts leading to alternative splicing in human cells.
In striking contrast to canonical regulators of alternative splicing
(e.g. SR proteins) that directly target pre-mRNAs by binding to
crucial cis-regulatory elements in pre-mRNAs via their characteris-
tic RNA-recognition motifs (Keren et al.,2010), Hub1by being incor-
porated into the spliceosome appears to stimulate certain splicing
events through altering the splicing machinery rather than by
targeting specific RNA substrates.
The other cellular phenotypes we observed upon prolonged
Hub1 depletion, like splicing speckle abnormalities, partial
nuclear pre-mRNA retention, mitotic defects and apoptosis, are
likely consequential effects caused by an accumulation of abnor-
mally spliced pre-mRNAs and perhaps their potentially harmful pro-
ducts. Indeed, generation of aberrantly spliced transcripts can
cause cellular stress, mis-regulation of various cellular pathways,
cell cycle defects and potentially cancer (Venables, 2004). It is of
note, however, that siRNA-mediated depletion of splicing factors
caused mitotic defects only for a fraction (30%) of spliceosomal
factors (Hofmann et al., 2010; Neumann et al., 2010) suggesting
that spliceosomes may perhaps directly influence the cell cycle.
Based on our study, it seems reasonable to assume that at least
some of the previously reported activities of Hub1 are linked to
Hub1’s role in splicing. However, as for the majority of proteins
of large protein assemblies like the spliceosome, the ribosome or
the nuclear pore, identifying the precise mechanistic explanation
for Hub1’s influence on splicing will be challenging. On the other
hand, the conserved ability of Hub1 to support alternative splicing
events indicates that mechanisms via modulating the spliceosome
apparently complement more elaborate control systems for alter-
native splicing that are conducted by trans-acting factors that
target the pre-mRNA.
Materials and methods
Yeast strains and plasmids
S. cerevisiae and S. pombe strains, complementation assays,
immunoblot analysis and SRC1 alternative splicing assays used
in this study were described previously (Mishra et al., 2011).










p415 ADH plasmid harboring coding sequences of S. cerevisiae,
S. pombe, and human HUB1 were used for complementation of
S. cerevisiae mutants. pREP81 plasmid harboring coding
sequences for S. cerevisiae, S. pombe, and human Hub1 were
used for complementation of the S. pombe mutant.
Plasmids and siRNA
Standard cloning techniques were used to generate mammalian
expression constructs in pEGFP-N1 (Clontech) or p3xFlag-CMV-10
(Sigma-Aldrich) vectors. The cDNA clone for hSnu66 (SART1) was
purchased from Origene, while the cDNA for human Hub1 (UBL5)
was amplified by RT–PCR using total RNA from HeLa cells.
Plasmids with point mutations or sequence deletions were con-
structed by site-directed mutagenesis using specific primers.
Genomic fragments of fibronectin 1 (FN1), tropomyosin 1a
(TPM), myeloid cell leukemia sequence 1 (MCL1), v-akt murine
thymoma viral oncogene homolog 1 (AKT), and aurora kinase A
(AURKA) for minigene constructs were amplified from genomic
human DNA (U2OS) by PCR and subcloned into modified pUB6/
V5 vectors (Invitrogen). For RNAi siRNA oligos were purchased
from MWG and designed as 19- or 21-mer duplexes with 3′
TT-overhangs according to criteria previously described (Elbashir
et al., 2001). siRNA duplexes targeting Hub1 in human cells were
iHub1_1 GGAAGAAGGUCCGCGUUAA, iHub1_2 CAAGAUUGUCCU
GAAGAAG, iHub1_3 AUAGAUGAGAAUCCUCAUC, iHub1_4 UGCAA
CACGGAUGAUACCA, iHub1_5 GGGAAGAAGGUCCGCGUUA, while
siRNACUAACAAACUCCGGGCAAA was used for hSnu66knockdown.
The GL2 siRNA targeting luciferase (Elbashir et al., 2001)
CGUACGCGGAAUACUUCGA was used as knockdown control. RNAi
of Son was performed with Silencer pre-designed siRNA (ID#
143161) from Ambion.
Human cell lines and transfections
The established cell lines HeLa, U2OS, and HEK293 T were main-
tained at 378C, 6% CO2 in DMEM (Invitrogen) supplemented with
10% fetal calf serum (FCS; Biochrom). HEK293T cells were trans-
fected using the calcium phosphate precipitation technique as
described previously (Bartke et al., 2004). Lipofectamine 2000
(Invitrogen) or Fugene HD (Roche) was used to transfect U2OS
and HeLa cells. For RNA interference (RNAi) experiments, cells
were transfected via electroporation with the Amaxa
Nucleofector II system (Lonza) or in 6-well plates using RNAiMax
(Invitrogen) with siRNA duplexes at a final concentration of 300
and 50 nM, respectively, according to the manufacturers’ protocol.
Due to highest knockdown efficiency Hub1 depletion and comple-
mentation experiments were performed using siRNA oligo iHub1_1
(Figures 3, 4B, 5 and Supplementary Figure S3–S5). However,
repetition of knockdown experiments with iHub1_3 RNAi led to
similar results. U2OS cells stably expressing GFP-Hub1 WT,
GFP-Hub1 D22A, and free GFP were generated by several rounds
of selection with750 mg/ml G418 (Sigma-Aldrich) after lipofection.
HeLa cells stably expressing histone variant H2B fused to green
fluorescent protein (H2B-GFP) were established as described
previously (Kanda et al., 1998) and examined in RNAi experiments
using live cell imaging. Fluorescence-activated cell sorting was
performed using the FACSAria cell sorter (Becton Dickinson) to
further enrich and purify GFP-positive cells.
Cell extracts and immunoprecipitation
Whole cell extracts were prepared by lysing human cells directly
in SDS Laemmli buffer. For immunoprecipitation, cells were har-
vested, washed in ice-cold PBS and cell pellets were lysed in 5×
pellet volumes of immunoprecipitation buffer (50 mM HEPES pH
7.2, 150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 1 mM PMSF,
and complete protease inhibitors (Roche)) at 48C for 30 min with
several passages through a 25 gauge needle attached to a
syringe. After removal of cell debris by centrifugation (10 min,
16000 g, 48C), cleared lysates were incubated with anti-FLAG M2
affinity gel (Sigma-Aldrich) or GFP trap (Chromotek) for 2 h at
48C. The affinity matrix was washed four times with immunopreci-
pitation buffer and eluted in SDS Laemmli buffer for later analysis
by SDS–PAGE and immunoblotting. For caspase activation assay,
cytosolic extracts were prepared as described previously
(Deveraux et al., 1999). Immunoblot quantification was performed
using the ImageJ software.
Flow cytometry and cell cycle synchronization
DNA histograms were obtained by flow cytometry analyses of
PI-stained ethanol-fixed cells using standard protocols (propidium
iodide 100 mg/ml (Sigma-Aldrich), RNase A 200 mg/ml (Sigma-
Aldrich) in PBS). FITC-labeled Annexin V (Sigma-Aldrich) and PI
(1 mg/ml) were used to detect the induction of apoptosis in
unfixed RNAi-treated cells according to the manufacturer’s protocol.
Data were acquired on a FACSCalibur system with CELLQuest soft-
ware (Becton Dickinson) and further analyzed with FlowJo software
(Tree Star). HeLa cells were synchronized following standard
double-thymidine block protocols using 2 mM thymidine.
Live cell imaging, immunofluorescence, and FISH analysis
For standard immunofluorescence microscopy, U2OS cells were
seeded and transfected on glass coverslips (Roth). Cells were
washed twice with PBS and fixed in 3.7% fresh paraformalde-
hyde/PBS for 18 min at room temperature. After fixation residual
formaldehyde was inactivated by quenching with PBS-glycine
(30 mM) and cells were washed three times in PBS. Permeabili-
zation of cells was performed using PBS-Triton X-100 0.4%
(6 min), followed by three PBS-Tween (Tween 0.05%; PBS-T)
washing steps and blocking in PBS-T with 2% BSA for 1 h at room
temperature. Coverslips were incubated with primary antibody
for 3 h (dilution 1:200 in blocking buffer) and then washed three
times in PBS-T. After incubation with secondary antibody, cover
slips were mounted using 4′,6-diamidino-2-phenylindole (DAPI)-
containing mounting medium (Vectashield, Vector Labs).
For pre-extraction experiments cells were permeabilized in CSK
buffer (100 mM NaCl, 300 mM sucrose, 10 mM PIPES pH 6.8) sup-
plemented with 0.4% Triton X-100 and complete protease inhibi-
tors (Roche) for 8 min at 48C. After two gentle wash-out steps
with detergent free CSK buffer, cells were fixed with3.7% formalde-
hyde. The following antibody staining was performed according to
the abovementioned standard protocol.










The RNA FISH method to visualize poly-adenylated mRNA using
fluorescently labeled poly-(dT)70-TRITC (MWG) probes (Dias et al.,
2010) was described previously (Tokunaga and Tani, 2008).
Images of several optical sections were acquired on a Zeiss
AxioImager Z1 microscope equipped with a CoolSNAP-HQ2 CCD
camera (Photometrics) and AxioVision Rel. 4.7 software (Zeiss).
In order to quantify the subcellular distribution of poly-adenylated
mRNA in RNAi-treated cells images were further processed with
CellProfiler analysis software (Carpenter et al., 2006). For cell seg-
mentation nuclei were identified by DAPI counterstaining while cell
body outlines were specified by phalloidin-FITC labeling (0.2 mg/
ml; Sigma-Aldrich) of cellular actin networks to subsequently
measure the integrated intensities of mRNA FISH signals in
nuclear and cytoplasmic regions.
After RNAi transfection, HeLa H2B-GFP cells were seeded on 4
well m-dishes (ibidi) and transferred into the BioStation IM live
cell imaging system (Nikon) for fluorescence time-lapse micros-
copy. Images were acquired every 8 min over a time frame of
24248 h with BioStation IM software and further processed by
Photoshop (Adobe).
Recombinant protein purification and crystallization
Vector (pET28a) harboring human HUB1 was expressed in
BL21-CodonPlus (DE3)-RIL cells (Stratagene) and the 6×His-
tagged protein was purified by Ni-NTA agarose beads (Qiagen), fol-
lowed by gel filtration on Superdex75 (GE Healthcare) in PBS buffer.
Proper folding of the protein was analyzed by 1D NMR spectrum
recorded by a 600-MHz Bruker NMR spectrometer. The hSnu66
HIND peptide, comprising residues 117–135 of hSnu66, containing
the sequence SLSIEETNKLRAKLGLKPL, was chemically synthesized.
For crystallization, purified Hub1 was mixed with the HIND
peptide at a molar ratio of 1:3 and the complex was separated by
gel filtration on Superdex 75 (GE Healthcare) in 10 mM Tris/HCl
pH 8.0, 100 mM NaCl, and 5 mM b-mercaptoethanol. The
complex was concentrated to 10–13 mg/ml and crystallized at
208C, using the sitting drop vapor diffusion method. The 2–3 ml
drops consisted of a 1:1 (v/v) mixture of protein solution and
well solution. Crystals appeared after 3 days and grew to final
size after 2 weeks of incubation. The best diffracting crystals of
the human Hub1/HIND complex grew in 0.1 M Tris/HCl pH 9.0,
0.15 M sodium acetate, 20% (w/v) PEG 4000. Crystals were
soaked in cryoprotection solution containing mother liquor supple-
mented with 30% glycerol and were snap frozen in liquid nitrogen.
Data collection and structure determination
A high quality X-ray dataset up to2.0 A˚ was collected at the Swiss
Light Source beamline PXII at Paul Scherrer Institute (Villigen,
Switzerland). The collected data were integrated, scaled and
merged by XDS and XSCALE programs (Kabsch, 1993) in space
group P21212.
The structure was determined by molecular replacement using
the Molrep program from the CCP4 suite ccp (Collaborative
Computational Project, Number 4, 1994) and the structure of the
Sc Hub1/HINDII complex as a search model (PDB entry 3PLV).
Refinement and model building were carried out with the
REFMAC5 (Collaborative Computational Project, Number 4, 1994)
and XtalViev/Xfit (McRee, 1999). The Arp/Warp (Lamzin and
Wilson, 1993) program was used to add water molecules. Certain
solvent exposed side-chains without clear electron density were
removed from the model. Data collection and refinement statistics
are shown in the Supplementary Table S1. The Ramachandran-plot
distribution for residues in the structure was95.4% in most favored
regions, 3.4% in allowed regions, 1.2% in disallowed regions. All
structural-model figures were generated by Pymol (http://www.
pymol.org/).
Antibodies
Antibodies used in this study were anti-a-tubulin (DM1A,
Sigma-Aldrich), anti-Caspase-7 (C7, Cell Signaling), anti-Caspase-3
(8G10, Cell Signaling), anti-GFP (clone B-2, Santa Cruz and ab1218,
Abcam), hnRNP I (sc-133667, Santa Cruz), anti-PRPF6 (sc-48786,
Santa Cruz), anti-PRPF8 (ab87433, Abcam), anti-TAP (PAP) (Sigma-
Aldrich), anti-hSnu66 (A301–423A, Bethyl), anti-SC35 (for immuno-
fluorescence: ab11826, Abcam; for immunoblotting: #556363, BD
Biosciences), anti-Son (HPA023535, Sigma-Aldrich), anti-2,2,7-
trimethylguanosine (K121, Calbiochem), anti-U1A (ab55751,
Abcam), anti-U2AF65 (ab37483, Abcam), anti-Sm antigen Y12
(ab3138, Abcam). For immunofluorescence Alexa Fluor 488- and
AlexaFluor555-labeled secondary goat anti-mouse anddonkeyanti-
rabbit/anti-mouse antibodies from Invitrogen were used.
Hub1-specific antibodies against recombinant S. cerevisiae Hub1
and human Hub1, respectively, were affinity-purified from serum
of immunized rabbits.
RNA isolation, reverse transcription, and PCR
Total RNA was isolated from RNAi-transfected cells using the
RNeasy kit (Qiagen) according to the manufacturer’s protocol.
Reverse transcription was performed with the Transcriptor First
Strand cDNA Synthesis Kit with random hexamers or poly-(dT)
primers (Roche), while subsequent transcript specific PCRs were
conducted using PfuTurbo DNA polymerase (Aligent). PCR pro-
ducts were analyzed on 2%22.5% ethidium bromide containing
agarose gels. Gene-specific primer sequences are listed in
Supplementary Table S2.
Splicing-sensitive microarray analysis
Exon expression profiling was performed using the GeneChip
Human Exon 1.0 ST Arrays (Affymetrix). Total RNA was isolated
from U2OS cells 60 h after Hub1 or control RNAi transfection
using the High Pure RNA Isolation Kit (Roche) according to the man-
ufacturer’s protocol. RNA samples of biological triplicates were
labeled and hybridized to the splicing-sensitive microarray for sub-
sequent bioinformatics analysis via Affymetrix Powertools (ATLAS
Biolabs GmbH) as described previously (Rasche and Herwig,
2010). Relative expression profiles of individual probes after
Hub1 or control knockdown in U2OS cells were processed using
the ARH method, resulting in metascores based on Splice index
(SI), P-value (P, log10), and arh-value (arh, .0.03 significant).
For initial analysis CEL files were processed using AltAnalyze soft-
ware (version 2.0) with core probe set filtering using DABG










(detected above background P-value cutoff 0.05) and microarray
analysis of differential splicing (MiDAS exon analysis parameters
P-value cutoff 0.05) (Gardina et al., 2006; Xing et al., 2008). The
resulting splice index corresponds to differential exon intensity
levels in Hub1 knockdown samples compared with control cells
after normalization.
Supplementary material
Supplementary material is available at Journal of Molecular Cell
Biology online.
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